# Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

> **NCT06325709** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 10 (estimated)

## Conditions studied

- Chronic Granulomatous Disease (CGD)
- X-Linked Chronic Granulomatous Disease

## Interventions

- **DRUG:** Plerixafor
- **DRUG:** Filgrastim
- **DRUG:** Palifermin
- **DRUG:** Busulfan
- **BIOLOGICAL:** Base-edited hematopoietic stem and progenitor cells
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT06325709
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-17
- **Primary completion:** 2032-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06325709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06325709, "Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06325709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*